Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: Impact of disease progression vs. adverse events

Ryosuke Ando, Kiyoshi Takahara, Toshiki Ito, Kent Kanao, Ikuo Kobayashi, Ryoichi Shiroki, Makoto Sumitomo, Hideaki Miyake, Takahiro Yasui

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: Impact of disease progression vs. adverse events'. Together they form a unique fingerprint.

Medicine & Life Sciences